<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02029157</url>
  </required_header>
  <id_info>
    <org_study_id>ARQ 197-009</org_study_id>
    <nct_id>NCT02029157</nct_id>
  </id_info>
  <brief_title>A Randomized Double-blind, Placebo-controlled Japanese Phase III Trial of ARQ 197 in Hepatocellular Carcinoma (HCC)</brief_title>
  <acronym>JET-HCC</acronym>
  <official_title>A Phase III Randomized Double-blind, Placebo-controlled Trial of ARQ 197 in Subjects With c-MET Diagnostic-high Inoperable Hepatocellular Carcinoma (HCC) Treated With One Prior Sorafenib Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyowa Hakko Kirin Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyowa Hakko Kirin Co., Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present clinical trial is aiming to evaluate efficacy of ARQ 197 in patients with
      hepatocellular carcinoma (HCC), who were resistant or intolerable to one systemic
      chemotherapy regimen including sorafenib.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">August 2017</completion_date>
  <primary_completion_date type="Actual">August 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Estimated median of 8-12 weeks in PFS</time_frame>
    <description>Progression-free survival will be compared between ARQ 197 group and Placebo group, to prove the efficacy of ARQ 197 in the population.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Estimated median of 24 weeks in overall survival</time_frame>
    <description>The date of the events was followed every three months after the end of the treatments of the study drug.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">386</enrollment>
  <condition>Liver Cancer</condition>
  <arm_group>
    <arm_group_label>ARQ 197</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily oral dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Daily oral dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARQ197</intervention_name>
    <arm_group_label>ARQ 197</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent form

          -  ≥20 years old

          -  Inoperable HCC which is not eligible for locoregional therapy

          -  Diagnosed as c-Met high in tumor sample

          -  Radiographic progression is confirmed during or after systemic chemotherapy including
             sorafenib, or those who are intolerance to the chemotherapy.

          -  Eastern Cooperative Oncology Group Performance Status (ECOG PS) is 0 or 1

          -  Child-Pugh Class A

          -  Having measurable target lesions which are defined by Response Evaluation Criteria in
             Solid Tumors (RECIST) version 1.1,

          -  Negative pregnancy test results

          -  Adequate organ function

          -  Life expectancy of at least 12 weeks

        Exclusion Criteria:

          -  More than 2 prior systemic chemotherapy.

          -  Prior therapy of c-Met inhibitor (including antibody)

          -  Any systemic therapy within ≤2 weeks prior to the randomization

          -  Locoregional therapy within ≤4 weeks prior to randomization.

          -  Major surgery within ≤4 weeks prior to the randomization

          -  Concurrent cancer within ≤5 years prior to the randomization

          -  History of cardiac diseases

          -  Active clinically serious infections defined as ≥ Grade 3 according to Common Toxicity
             Criteria for Adverse Effects (CTCAE) 4.0

          -  Any psychological disorder affecting Informed Consent

          -  Diagnosis positive for anti-HIV antibody and/or anti-HTLV-1 antibody

          -  Blood or albumin transfusion within ≤14 days prior to the screening test

          -  Concurrent interferon therapy against Hepatitis B Virus (HBV)/ Hepatitis C Virus (HCV)

          -  Symptomatic brain metastases

          -  History of liver transplantation

          -  Inability to swallow oral medications

          -  Confirmed interstitial lung disease

          -  Pleural effusion and/or clinically significant ascites

          -  Pregnancy or breast-feeding

          -  Without consent to effective single or combined contraceptive methods
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cancer Centers in Japan</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 27, 2013</study_first_submitted>
  <study_first_submitted_qc>January 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2014</study_first_posted>
  <last_update_submitted>October 6, 2017</last_update_submitted>
  <last_update_submitted_qc>October 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

